Changes

no edit summary
Line 11: Line 11:  
! REFERENCES
 
! REFERENCES
 
|-
 
|-
| GLIOMAS
+
|'''GLIOMAS'''
 
|
 
|
 
|
 
|
Line 206: Line 206:  
|PMID:22832581; PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768  PMID:20940197 PMID:23175120
 
|PMID:22832581; PMID:25043047; PMID:24493713 PMID:23175120; PMID:22134537; PMID:22832581; PMID:24493713; PMID:22358457; PMID:25043047 PMID:22820256; PMID:26976201; PMID:20823417 PMID:22265402; PMCID:3889646; PMID:16567768  PMID:20940197 PMID:23175120
 
|-
 
|-
 +
|Atypical teratoid/rhabdoid tumor (AT/RT)
 +
|
 +
|'''Loss:''' 22/22q, though a subset of AT/RT-like tumors retain 22q
 +
|Classic AT/RT: SMARCB1 mutation/deletion/exonic duplication in 98% of tumors<br>
 +
AT/RT-like tumors: SMARCB1 can be retained (with SMARCA4 mutations)<br>
 +
'''Three molecular classes:'''<br>
 +
'''TYR:''' ~ 75% show broad 22q loss that includes SMARCB1<br>
 +
'''SHH:''' ~ 50% lack any SMARCB1 mutation; ~ 25% have focal SMARCB1 aberrations<br>
 +
'''MYC:''' ~ 75% show focal SMARCB1 loss
 +
|Most cases occur before 3 yrs of age<br>
 +
TYR subclass: mostly infratentorial<br>
 +
SHH subclass: supra/infratentorial<br>
 +
MYC subclass: mostly supratentorial
 +
|
 +
|-
 +
|Embryonal tumor with multilayered rosettes, C19MC-altered
 +
|
 +
|'''ETMR (incl. ETANTR):''' occasionally polysomy 2
 +
|'''ETANTR:''' miRNA cluster C19MC amplification
 +
|Occurs mainly in children < 4 yrs old
 +
| WHO CNS Tumors (2016)<br>
 +
PMID:24839957; PMID:24470553 PMID:24337497; PMID:22324795 PMID:20407781, PMID:19057917
 +
|-
 +
|Embryonal tumor, other
 +
|
 +
|'''CNS NB-FOXR2 group:''' 1q gain, 16q loss, polysomy 8<br>
 +
'''CNS EFT-CIC group:''' polysomy 8<br>
 +
'''CNS HGNET-MN1 group:''' 16q loss, polysomy 8<br>
 +
'''CNS HGNET-BCOR group:''' mostly balanced genomes
 +
|'''CNS NB-FOXR2 group:''' JMJD1C fusions, FOXR2 fusion or deletion<br>
 +
'''CNS EFT-CIC group:''' NUTM1 rearrangement/fusion, CIC rearrangement<br>
 +
'''CNS HGNET-MN1 group:''' MN1 rearrangement <br>
 +
'''CNS HGNET-BCOR group:''' BCOR intragenic tandem duplication
 +
|Most common in children, but may also occur in adolescents and adults
 +
|WHO CNS Tumors (2016)<br>
 +
PMID:26919435; PMID:22691720; PMID:22772606
 +
|-
 +
|'''CHOROID PLEXUS TUMORS (CPT)'''
 +
|Choroid plexus papilloma(CPP, WHO grade I) and atypical choroid plexus papilloma (WHO grade II)
 +
|'''Hyperdiploidy'''<br>
 +
'''Loss:''' rare, no recurrent losses                                                                   
 +
|No diagnostic mutations/events
 +
|CPP and aCPP likely belong to same molecularly defined entity; CPP is a diagnostic feature of Aircardi syndrome
 +
|WHO CNS Tumors (2016)<br>
 +
PMID:23172371; PMID:25575132; PMID:25336695 PMID:11891207
 +
|-
 +
|
 +
|Choroid plexus carcinoma (CPC, WHO grade III)
 +
|'''Aneuploidy''' (including both hypo- and hyperdiploidy types of CPC); copy neutral LOH is frequent, particularly involving chromosome 17<br>
 +
'''Gain:''' 1, 7, 12, 20 in > 80% of hyperdiploid CPCs<br>
 +
'''Loss:''' 3 (in all hypodiploid CPC), 6, 11, 12q, 16, 22
 +
|'''Mutation:''' TP53 in > 50%<br>
 +
'''Amplification:''' PDGFRB
 +
|80% occur in children; associated with Li-Fraumeni syndrome; Lack of SMARCB1/SMARCA4 aberrations can be used to distinguish CPC from AT/RT
 +
|PMID:24478045; PMID:21990040; PMID:25575132; PMID:18157090; PMID:25336695